Caplacizumab Improves Clinical Outcomes and is Well Tolerated Across Clinically Relevant Subgroups of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura
Research and Practice in Thrombosis and Haemostasis（2024）
Key words
caplacizumab,efficacy,prognosis,thrombotic thrombocytopenic purpura,treatment outcome
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined